SHIRE PHARMACEUTICALS LLC for SHIRE PHARMACEUTICALS LLC
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Committee on Foreign Investment in the United States (CFIUS) reform
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARGARET MANN | — |
Taxation/Internal Revenue Code TAX
Orphan drug tax credit
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARGARET MANN | — |
Copyright/Patent/Trademark CPT
HR 5340/S1390: Stronger Patents Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARGARET MANN | — |
Health Issues HCR
HR 2587/S1194: Medical Nutrition Equity Act of 2017 HR6: Support for Patients and Communities Act 340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARGARET MANN | — |
Medicare/Medicaid MMM
- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - HR 4724: Medicare IVIG Access Enhancement Act - Medicare Part D
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARGARET MANN | — |
Pharmacy PHA
-Medicaid rare disease patient access to therapy Patient access to therapy, including Medicaid, Medicare, and insurance. -Orphan Drug Act regulations -Expanded Access -Rare Disease awareness -Newborn Screening
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARGARET MANN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.